Allogene Therapeutics, Inc.
ALLO
$1.77
-$0.09-4.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.14% | 31.14% | 25.90% | 25.20% | 15.22% |
| Total Depreciation and Amortization | -7.73% | -8.00% | -9.38% | -9.71% | -11.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.22% | -47.13% | -41.33% | -46.74% | -26.01% |
| Change in Net Operating Assets | 263.76% | 157.53% | 56.14% | 84.62% | 76.67% |
| Cash from Operations | 40.85% | 44.65% | 25.49% | 27.13% | 24.46% |
| Capital Expenditure | 51.51% | 62.29% | 44.38% | -4.05% | -312.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -540.52% | -0.70% | 25.61% | 32.30% | -77.12% |
| Cash from Investing | -554.53% | 0.11% | 26.25% | 32.49% | -77.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,084.80% | -72.66% | -79.68% | -80.58% | -83.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -36.80% | 202.98% | 202.98% | 202.98% |
| Cash from Financing | 763.64% | -71.10% | -74.15% | -74.76% | -77.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.42% | -41.50% | -196.46% | 25.45% | -843.82% |